BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s): BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp.

<< Previous

Bullboard Posts

Next >>

Post by Bomdrou999on Oct 20, 2021 8:19am

99 Views

Post# 34026006

And now...

... watch the conference today

Details of the poster presentation are as follows:

Title: A Novel Hapten-Modified SARS-CoV-2 Spike Protein Vaccine (BVX-0320) Induces Antibody and T Cell Responses in a Murine Model
Author: David Berd, MD, BioVaxys Technology Corp.
Poster Viewing Times: October 19 , 17:35 CET ; October 20 , 17:30 CET